1.Targeting HER2 in the Treatment of Ductal Carcinoma in Situ (Posted: 10/06/2009) - In this clinical trial, women with HER2-positive DCIS will be treated with lumpectomy followed by whole-breast radiation therapy; half of the women will also receive two doses of trastuzumab during their radiation treatment. 2.Testing a New Drug in Advanced BRCA-related Cancer (Posted: 09/08/2009) - In this clinical trial, women with advanced breast or ovarian cancer who carry a known BRCA gene mutation or who have a strong family history of these diseases (and are, therefore, likely to carry such a mutation) will be treated with a new drug called AZD2281 (olaparib) together with the chemotherapy drug carboplatin. 3.Optimizing Postoperative Chemotherapy for Breast Cancer (Posted: 06/16/2009) - In this trial, women with early-stage breast cancer deemed by their doctors to be at high risk for recurrence will receive adjuvant chemotherapy with either cyclophosphamide and doxorubicin or paclitaxel given four times over an 8-week period. 4.Targeting Resistance to Endocrine Therapy in Advanced Breast Cancer (Posted: 04/07/2009) - In this phase III clinical trial, women with advanced, hormone receptor-positive breast cancer will be randomly assigned to receive hormonal therapy (with letrozole or tamoxifen) and either bevacizumab or a placebo. 5.Enhancing Cancer Information Materials with Multimedia (Posted: 02/10/2009) - Patients with newly diagnosed prostate or breast cancer or who are finishing or recently completed breast cancer treatment and who call the NCI's Cancer Information Service for information will be invited to participate in a trial of multimedia information during the call.
